

Abishek Chandrashekar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1351353/publications.pdf>

Version: 2024-02-01

54
papers

9,490
citations

196777

29
h-index

169272

56
g-index

71
all docs

71
docs citations

71
times ranked

15919
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634.	13.7	995
2	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020, 369, 806-811.	6.0	978
3	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020, 584, 443-449.	13.7	956
4	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817.	6.0	789
5	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	13.7	765
6	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. <i>Science</i> , 2016, 353, 1129-1132.	6.0	461
7	Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. <i>Nature</i> , 2022, 603, 493-496.	13.7	326
8	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2370.	3.8	307
9	Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. <i>New England Journal of Medicine</i> , 2022, 386, 1579-1580.	13.9	296
10	Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021, 596, 268-272.	13.7	290
11	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. <i>Immunity</i> , 2017, 46, 1073-1088.e6.	6.6	286
12	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018, 392, 232-243.	6.3	269
13	Immunogenicity of the Ad26.COVS Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	3.8	260
14	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016, 540, 284-287.	13.7	246
15	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , 2018, 563, 360-364.	13.7	246
16	Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2021, 385, 2010-2012.	13.9	228
17	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COVS Vaccination. <i>New England Journal of Medicine</i> , 2021, 385, 951-953.	13.9	192
18	Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. <i>Cell</i> , 2017, 169, 610-620.e14.	13.5	191

#	ARTICLE	IF	CITATIONS
19	Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. <i>Cell</i> , 2020, 183, 1354-1366.e13.	13.5	184
20	Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. <i>Science</i> , 2016, 353, 1045-1049.	6.0	129
21	Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	108
22	Profiling SARS-CoV-2 HLA-I peptidome reveals T _H cell epitopes from out-of-frame ORFs. <i>Cell</i> , 2021, 184, 3962-3980.e17.	13.5	98
23	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.	13.7	71
24	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. <i>Cell</i> , 2022, 185, 1549-1555.e11.	13.5	59
25	Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. <i>Science Translational Medicine</i> , 2022, 14, eabn6150.	5.8	57
26	Low-dose Ad26.COVS.2 protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11.	13.5	49
27	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	1.5	40
28	Protective efficacy of Ad26.COVS.2 against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	13.7	40
29	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021, 27, 1718-1724.	15.2	39
30	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1061-1070.	4.6	36
31	Lack of therapeutic efficacy of an antibody to $I\pm ₄^2 ₇$ in SIVmac251-infected rhesus macaques. <i>Science</i> , 2019, 365, 1029-1033.	6.0	31
32	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques. <i>Science Advances</i> , 2022, 8, eabl6015.	4.7	27
33	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. <i>Nature Communications</i> , 2021, 12, 1474.	5.8	26
34	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020, 183, 185-196.e14.	13.5	25
35	SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COVS.2 vaccination predict durable protection in rhesus macaques. <i>Nature Communications</i> , 2021, 12, 5877.	5.8	21
36	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP) Tj ETQq0 0.0 rgBT /Overlock 10		

#	ARTICLE	IF	CITATIONS
37	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. <i>Science Translational Medicine</i> , 2021, 13, eabj2641.	5.8	15
38	Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. <i>Journal of Infectious Diseases</i> , 2022, 225, 1124-1128.	1.9	15
39	HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys. <i>PLoS Pathogens</i> , 2022, 18, e1010467.	2.1	15
40	Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens. <i>Vaccine</i> , 2017, 35, 1-9.	1.7	14
41	Long-acting capsid inhibitor protects macaques from repeat SHIV challenges. <i>Nature</i> , 2022, 601, 612-616.	13.7	14
42	A homologous or variant booster vaccine after Ad26.COVS immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, eabm4996.	5.8	13
43	Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. <i>Nature Communications</i> , 2022, 13, .	5.8	12
44	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. <i>Med</i> , 2022, 3, 188-203.e4.	2.2	11
45	Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation. <i>Nature Communications</i> , 2020, 11, 5412.	5.8	9
46	Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	8
47	Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika-specific antibodies. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13288.	1.2	7
48	Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice. <i>PLoS Pathogens</i> , 2021, 17, e1009673.	2.1	7
49	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. <i>Journal of Virology</i> , 2020, 94, .	1.5	5
50	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2022, 96, JVI0159921.	1.5	5
51	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. <i>Npj Vaccines</i> , 2022, 7, 53.	2.9	4
52	A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	3
53	Ad26.COVS boosts antibody and T-cell responses following BNT162b2 vaccination. <i>Emerging Microbes and Infections</i> , 2021, 10, 2220-2222.	3.0	2
54	Passive transfer of Ad26.COVS-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. <i>Npj Vaccines</i> , 2022, 7, 2.	2.9	2